| 亞洲大學 |
2010.06 |
Two Facility Selection Location Problem with Distance Based Attractiveness
|
王聖權;Wang, Sheng-Chuan |
| 中華大學 |
2006 |
Two Fast Architectures for 2-D DWT and IDWT Using 4-Tap Daubechies Filters
|
宋志雲; Sung, Tze-Yun |
| 中華大學 |
2005 |
Two Fast Architectures for Two-Dimensional Discrete Wavelet Transform and Its Inversion Using Direct Form
|
宋志雲; Sung, Tze-Yun |
| 國立成功大學 |
2018 |
Two fatal cases of Aeromonas dhakensis bacteremia and necrotizing fasciitis in severe dengue patients
|
Chang, H.-L.;Chen, P.-L.;Lin, S.-Y.;Chen, T.-C.;Chang, K.;Ko, W.-C.;Lu, P.-L.;Chen, Y.-H. |
| 臺大學術典藏 |
2020-06-30T06:14:01Z |
Two fatal cases of Veillonella bacteremia [2]
|
Liu J.W.;Wu J.J.;Wang L.R.;Lee-Jene Teng;Huang T.C.; Liu J.W.; Wu J.J.; Wang L.R.; LEE-JENE TENG; Huang T.C. |
| 國立臺灣科技大學 |
2016 |
Two FBG spectral convolution for strain sensing
|
Hsu, S.-H.;Chuang, K.-W.;Chen, Chen C.-S. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-04-23T05:56:30Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Hsu C.-H.;Chih-Hsin Yang;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; CHIH-HSIN YANG; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
